Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing compound doai
Reexamination Certificate
2007-03-13
2007-03-13
Tate, Christopher R. (Department: 1655)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing compound doai
C514S470000, C514S740000, C514S171000, C514S179000, C514S312000, C514S882000, C514S929000
Reexamination Certificate
active
10669099
ABSTRACT:
A pharmaceutical composition contains a nitric oxide donor and advantageously an optional corticosteroid and/or topical anesthetic. The composition is useful in a method for treating anal disorders such as anal fissure, anal ulcer, hemorrhoidal disease, levator spasm, and so forth, by topical application to or proximate the affected area.
REFERENCES:
patent: 814408 (1906-03-01), Steele
patent: 2840080 (1958-06-01), Clark
patent: 3419571 (1968-12-01), Di Carlo et al.
patent: 4118480 (1978-10-01), Williams
patent: 4226849 (1980-10-01), Schor
patent: 4292299 (1981-09-01), Suzuki et al.
patent: 4371516 (1983-02-01), Gregory et al.
patent: 4514384 (1985-04-01), Gallina
patent: 4608249 (1986-08-01), Otsuka et al.
patent: 4654209 (1987-03-01), Leslie et al.
patent: 4657906 (1987-04-01), Emmett et al.
patent: 4683242 (1987-07-01), Poser
patent: 4746675 (1988-05-01), Makino et al.
patent: 4842854 (1989-06-01), Babaian et al.
patent: 5047230 (1991-09-01), Nagy et al.
patent: 5059603 (1991-10-01), Rubin
patent: 5085650 (1992-02-01), Giglio
patent: 5183663 (1993-02-01), Greiner
patent: 5439938 (1995-08-01), Snyder et al.
patent: 5504117 (1996-04-01), Gorfine
patent: 5508045 (1996-04-01), Harrison et al.
patent: 5595753 (1997-01-01), Hechtman
patent: 5595970 (1997-01-01), Garfield et al.
patent: 5693676 (1997-12-01), Gorfine
patent: 5827889 (1998-10-01), Cunico
patent: PM 6395 (1994-07-01), None
patent: 74545/94 (1994-08-01), None
patent: PM 0971 (1995-03-01), None
patent: PM 4247 (1995-03-01), None
patent: 304730 (1989-03-01), None
patent: 4038203 (1992-06-01), None
patent: 62-67017 (1987-03-01), None
patent: 04-091036 (1996-03-01), None
patent: WO 87/03490 (1987-06-01), None
patent: WO 95/06466 (1995-03-01), None
patent: WO 98/36733 (1998-08-01), None
patent: WO 98/37886 (1998-09-01), None
patent: 77/01135 (1977-02-01), None
patent: 9500511 (1996-03-01), None
Loder et al. “Topical Application of Nitric Oxide Donor Reduces Internal Anal Sphinter Tone: Therapeutic Implications”. Gut. Apr. 1993. Abstract S25 (T96).
Loder et al. “Topical Glyceryl Trinitrate (GTN): Reversible Chemical Sphicterotomy”. Am Society of Colon and Rectal Surgeons 92nd An Conv Podium and Poster Abstracts, Chicago, IL. May 2-7, 1993. Dis Colon Rectum Meeting Abstrs, Apr. 1993, P22(64).
Guillemot et al. “Action of in Situ Nitroglycerin on Upper Anal Canal Pressure of Patients with Terminal Constipation—A Pilot Sudy”. Dis. Colon Rectum. Apr. 1993, pp. 372-376.
Jensen, S. “Treatment of First Episodes of Acute Anal Fissure: Prospective Randomised Study of Lignocaine Ointment Vs. Hydrocortisone Olntment or Warm Sitz Baths Plus Bran”. 1996.
Ahlner et al., “Organic Nitrate Esters: Clinical Use and Mechanisms of Actions.”Pharmacol. Reviews43(3):351-353 (1991).
Budavari et al. (Eds.), “The Merck Index.” pp. 198 and 821 (isopropyl nitrate); 11th Edition, Merck & Co., Rahway, N.J. (1989).
Bult et al., “Nitric oxide as an inhibitory non-adrenergic non-cholinergic neurotransmitter.”Nature, 345:346-347, 1990.
Burleigh, D. and D'Mello, A., “Physiology and Pharmacology of the Internal Anal Sphincter.” Chapter 2, pp. 22-41, inColoproctology and The Pelvic Floor, Henry and Swash (Eds.), Butterworth Publishers, Stoneham, Mass., USA and London, England, ISBN 0-407-00352-5 (1985).
Burleigh, D., “Ng-Nitro-L-Arginine Reduces Nonadrenergic Relexations of Human Gut.”Gastroenterology, 102: 679-683 (1992).
Chakder, et al. “Release of nitric oxide by activation of nonadrenergic honcholinergic neurons of internal anal sphincter.”NO Release By Nanc Naural Simulation and VIP, G7-12 (1992).
Enck et al., “Spontaneous variation of anal ‘resting’ pressure in healthy humans.”Am. J. Physiol., 261(5 Pt 1):G823-G826 (1991).
Farouk et al., “Sustained Internal Sphincter Hypertonia in Pa7tients with Chronic Anal Fissure.”Dis. Col. Rect., 37:424-429 (1994).
Feelisch et al., “Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase.”Eur. J. Pharmacol., 139:19-30 (1987).
Fung et al., “Biochemical mechanism of organic nitrate action.”Am. J. Cardiol., 70:4B-10B (1992).
Gibbons et al., “Anal hypertonia in fissures; cause or effect?”Br. J. Surg., 73:443-445 (Jun. 1986).
Gillespie et al., “Influence of hemoglobin and erythrocytes on the effects of EDRF, a smooth muscle inhibitory factor, and nitric oxide on vascular and non-vascular smooth muscle.”Br. J. Pharmacol., 95:1151-1156, 1988.
Gorfine, SR., 1995, “Treatment of benign anal disease with topical nitroglycerin.”Dis. Col. Rect., 38(5):453-456.
Guillernot et al., “Nitroglycerin In Situ Reduces Upper Anal Cause Pressure.”Digest. Dis. Sci., 37(1):155 (1992).
Guillernot et al., “Action ofin situnitroglycerin on upper anal canal pressure of patients with terminal constipation. A pilot study.”Dis. Col. Rect., 36(4):372-376 (1993).
Huff et al., (Eds.), “Physician' Desk Reference.” 41st Edition, Medical Economics Company, Oradell, N.J., at pp. 780, 1176-1178, 1533 and 1984-85 (1987).
Ignarro et al., “Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle.”Biochem. Biophys. Res. Commun., 170:843-850, 1990.
Jalan, K. et al., “Perineal Wound Healing in Ulcerative Colitis.”British Journal of Surgery(Oct. 1969) 56(10):749-53.
Jensen, S. “Treatment of first episodes of acute anal fissure: Prospective radomized study of lignocaine ointment versus hydrocortisone ointment or warm sitz bath plus bran.”Br. Med. J., 292(6529):1167-9 (1986).
Keigthley, R. and Williams, N..“Anatomy and Physiology.” Chapter One, inSurgery of the Anus, Rectum and Colon, London, W.B. Saunders (1993).
Kennedy, M. et al, “Chemical Sphincterotomy for Anal Fissure—A New Treatment.” Abstract CR33, presentation at Royal Australasian College of Surgeons at Hobart, Tasmania meeting of May 1-6, 1994.
Kennedy, M. et al., “Glyceryl Trinitrate Ointment for the Treatment of Chronic Anal Fissure.”Dis Colon Rectum42(8):1000-1006 (Aug. 1999).
Loder, P. et al, “‘Reversible chemical sphincterotomy’ by local application of glyceryl trinitrate.”Br. J. Surg., 81: 1386-1389 (1994).
Loder, P. et al, “Topical Application of a Nitric Oxide Donor Reduces Internal Anal Sphincter Tone: Therapeutic Implications.”Gut34:S25 (1993) Abstract also published inAGA Abstracts, Gastroenterology, 104: A544 (1993).
Loder, P. et al., “Topical Glyceryl Trinitrate (GTN): Reversible Chemical Sphincterotomy.” Meeting Abstracts.Dis. Col. Rect., 33:22 (Apr. 1993).
Lord, P., “A Day-Case Procedure for the Cure of Third-Degree Haemorrhoids.”Br. J. Surg. 56(10):47-9 (1969).
Lubowski, D. et al., “Neural control of internal anal sphincter function.”Br. J. Surg. 74: 668-670 (Aug. 1987).
Lund, J. and Scholefield, J., “A randomised, prospective, double-blind, placebo-controlled trial of glyceryl trinitrate ointment in treatment of anal fissure.”Lancet, 349: 11-14 (Jan. 4, 1997).
Lund, J. et al., “Use of glyceryl trinitrate ointment in the treatment of anal fissure.” British Journal of Surgery 83: 776-777 (1996).
MacDonald, A. et al., “Manual dilation of the anus.”British Journal of Surgery79:1381-1382 (Dec. 1992).
Mims Annual Drug Reference, Fifteenth Edition, 2-75, p. 2042 (1991).
O'Kelley, T. et al, “Nerve mediated relaxation of the human internal anal sphincter: the role of nitric oxide.”Gut, 34: 689-693 (1993).
Rattan, S. and Chakder, S., “Role of nitric oxide as a mediator of internal anal sphincter relaxation.”Am. J. Physiol. G107-G112 (1992).
Rattan, S. et al., “Nitric Oxide Pathway in Rectoanal Inhibitory Reflex of Opossum In
Tate Christopher R.
Townsend and Townsend / and Crew LLP
LandOfFree
Nitric oxide donor composition and method for treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitric oxide donor composition and method for treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitric oxide donor composition and method for treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3765014